Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Ther Adv Neurol Disord
.
2021 May 29:14:17562864211020082.
doi: 10.1177/17562864211020082.
eCollection 2021.
Authors
Anat Achiron
1
,
Mathilda Mandel
2
,
Sapir Dreyer-Alster
2
,
Gil Harari
2
,
David Magalashvili
2
,
Polina Sonis
2
,
Mark Dolev
2
,
Shay Menascu
2
,
Shlomo Flechter
2
,
Rina Falb
2
,
Michael Gurevich
2
Affiliations
1
Multiple Sclerosis Center, Sheba Medical Center, 2 Derech Sheba, Ramat-Gann, 52621, Israel.
2
Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
PMID:
34104221
PMCID:
PMC8165862
DOI:
10.1177/17562864211020082
No abstract available
Keywords:
COVID-19; cladrivine; finfolimod; mRNA vaccine; multiple sclerosis; ocrelizumab.